Similarly, FAK inhibitor IN10018, when combined with PEGylated liposomal doxorubicin (PLD) demonstrated synergistic effects, increasing tumor‐infiltrating lymphocytes and promoting immunogenic cell death [146]. The gene discussed is PTK2; the disease is neoplasm.